公开(公告)号：US10017782B2

公开(公告)日：2018-07-10

申请号：US15012285

申请日：2016-02-01

申请人： Yale University

发明人： Peter M. Rabinovich ,  Sherman M. Weissman ,  Erkut Bahceci ,  Marina E. Komarovskaya

IPC分类号： A61K9/66 ,  C12N15/85 ,  A61K48/00 ,  C12N5/074 ,  A61K35/17 ,  A61K35/33 ,  A61K35/36 ,  A61K35/12

CPC分类号： C12N15/85 ,  A61K35/17 ,  A61K35/33 ,  A61K35/36 ,  A61K48/005 ,  A61K2035/124 ,  C12N5/0696 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2506/094 ,  C12N2506/1307 ,  C12N2510/00

摘要： RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system.

公开(公告)号：US20170198255A1

公开(公告)日：2017-07-13

申请号：US15427986

申请日：2017-02-08

申请人： Steven A. GOLDMAN ,  Su WANG

发明人： Steven A. GOLDMAN ,  Su WANG

IPC分类号： C12N5/079 ,  A61K9/00 ,  A61K35/30

CPC分类号： C12N5/0622 ,  A61K9/0085 ,  A61K35/30 ,  C12N2506/02 ,  C12N2506/094 ,  C12N2506/45

摘要： The present invention relates to preparations of induced pluripotent cell-derived oligodendrocyte progenitor cells, and methods of making, isolating, and using these preparations.

公开(公告)号：US09005968B2

公开(公告)日：2015-04-14

申请号：US13500373

申请日：2010-10-15

申请人： Tongxiang Lin ,  Sheng Ding

发明人： Tongxiang Lin ,  Sheng Ding

IPC分类号： C12N5/00 ,  C12N5/074

CPC分类号： C12N5/0696 ,  C12N2501/065 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/094 ,  C12N2506/1307 ,  C12N2506/28 ,  C12N2510/00

摘要： The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.

摘要翻译： 用于产生人诱导多能干细胞（iPSCs）的重编程方法的缓慢动力学和低效率对其在生物医学应用中的实用性施加了主要限制。 在这里，我们描述了一种化学方法，在治疗后7天内显着改善（> 200倍）来自人成纤维细胞的iPSC生成的效率。 这将为重新编程人体细胞提供更安全，更有效，非病毒的方法的基础。

公开(公告)号：US20120220034A1

公开(公告)日：2012-08-30

申请号：US13504988

申请日：2010-11-01

申请人： Jan-Eric Ahlfors ,  Rouwayda Elayoubi

发明人： Jan-Eric Ahlfors ,  Rouwayda Elayoubi

IPC分类号： C12N5/071 ,  C12N5/0797

CPC分类号： C12N5/0623 ,  A61K35/30 ,  A61K35/545 ,  C12N5/0618 ,  C12N5/0619 ,  C12N5/0647 ,  C12N5/0656 ,  C12N5/0657 ,  C12N5/0662 ,  C12N5/0667 ,  C12N5/0668 ,  C12N5/0676 ,  C12N5/0696 ,  C12N2500/25 ,  C12N2501/06 ,  C12N2501/065 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/13 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/395 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/604 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2506/094 ,  C12N2506/11 ,  C12N2506/1307 ,  C12N2506/1346 ,  C12N2506/1384 ,  C12N2510/00

摘要： Described herein are methods for cell dedifferentiation, transformation and eukaryotic cell reprogramming Also described are cells, cell lines, and tissues that can be transplanted in a patient after steps of in vitro dedifferentiation and in vitro re-programming In particular embodiments the cells are Stem-Like Cells (SLCs), including Neural Stem-Like Cells (NSLCs) Also described are methods for generating these cells from human somatic cells and other types of cells Also provided are compositions and methods of using of the cells so generated in human therapy and in other areas.

摘要翻译： 本文描述了用于细胞去分化，转化和真核细胞重编程的方法。还描述了在体外去分化和体外重新编程的步骤之后可以移植到患者中的细胞，细胞系和组织。在特定实施方案中，细胞是Stem- 类似细胞（SLC），包括神经干细胞样细胞（NSLC）也描述了从人体细胞和其它类型的细胞产生这些细胞的方法。还提供了使用在人类治疗中如此产生的细胞的组合物和方法 其他地区。

公开(公告)号：US20120189595A1

公开(公告)日：2012-07-26

申请号：US13120727

申请日：2009-09-25

申请人： Angel Raya ,  Trond Aasen ,  Juan Carlos Izpisua Belmonte

发明人： Angel Raya ,  Trond Aasen ,  Juan Carlos Izpisua Belmonte

IPC分类号： A61K35/12 ,  C12N15/867 ,  A61P17/00 ,  C12N5/10 ,  C12N15/85

CPC分类号： C12N5/0696 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2506/094 ,  C12N2510/00

摘要： The invention relates to the field of stem cells and, specially, to the reprogramming of adult somatic cells; to obtain pluripotent cells by the transfection of specific genes. Thus, the invention provides induced pluripotent stem cells (iPS) and methods of obtaining and using them.

公开(公告)号：US12129484B2

公开(公告)日：2024-10-29

申请号：US16659110

申请日：2019-10-21

申请人： UNIVERSITY OF ROCHESTER

发明人： Steven A. Goldman ,  Su Wang

IPC分类号： A61K35/30 ,  A61K9/00 ,  C12N5/079 ,  C12N5/0735

CPC分类号： C12N5/0622 ,  A61K9/0085 ,  A61K35/30 ,  C12N5/0606 ,  C12N2506/02 ,  C12N2506/094 ,  C12N2506/45

摘要： The present disclosure relates to a preparation of CD140a/PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM− sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.

公开(公告)号：US12024722B2

公开(公告)日：2024-07-02

申请号：US16125528

申请日：2018-09-07

申请人： Genesis Technologies Limited

发明人： Jan-Eric Ahlfors ,  Rouwayda El-Ayoubi

IPC分类号： C12N5/00 ,  C12N5/071 ,  C12N5/074 ,  C12N5/0775 ,  C12N5/0789 ,  C12N5/0797 ,  C12N15/85

CPC分类号： C12N5/0696 ,  C12N5/0623 ,  C12N5/0647 ,  C12N5/0662 ,  C12N5/0678 ,  C12N15/85 ,  C12N2501/40 ,  C12N2501/60 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/998 ,  C12N2502/99 ,  C12N2506/094 ,  C12N2506/11 ,  C12N2506/1307 ,  C12N2506/1384

摘要： Described herein are reprogrammed cells, and methods for cell dedifferentiation, transformation and eukaryotic cell reprogramming. Also described are cells, cell lines, and tissues that can be transplanted in a patient after steps of in vitro dedifferentiation and in vitro reprogramming. In particular embodiments the cells are Stem-Like Cells (SLCs), including Neural Stem-Like Cells (NSLCs), Cardiac Stem-Like Cells (CSLC), Hematopoietic Stem-Like Cells (HSLC), Pancreatic Progenitor-Like Cells, and Mesendoderm-like Cells. Also described are methods for generating these cells from human somatic cells and other types of cells. Also provided are compositions and methods of using of the cells so generated in human therapy and in other areas.

公开(公告)号：US20230374460A1

公开(公告)日：2023-11-23

申请号：US18362365

申请日：2023-07-31

申请人： The Trustees of Columbia University in the City of New York

发明人： Masayuki Yazawa ,  LouJin Song

IPC分类号： C12N5/077 ,  C12N5/074

CPC分类号： C12N5/0657 ,  C12N5/0696 ,  C12N2501/999 ,  C12N2500/90 ,  C12N2506/1307 ,  C12N2506/45 ,  C12N2506/094 ,  C12N2500/99 ,  C12N2501/33 ,  C12N2501/727 ,  C12N2500/02 ,  C12N2501/415

摘要： The present invention relates to monolayer cardiac differentiation techniques utilizing defined conditions providing feeder-free monolayer culture systems, serum-based or serum free, and applicable to both healthy control and patient derived stem cells.

公开(公告)号：US20180163181A1

公开(公告)日：2018-06-14

申请号：US15875928

申请日：2018-01-19

申请人： The Scripps Research Institute

发明人： Tongxiang Lin ,  Sheng Ding

IPC分类号： C12N5/074

CPC分类号： C12N5/0696 ,  C12N2501/065 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/094 ,  C12N2506/1307 ,  C12N2506/28 ,  C12N2510/00

摘要： The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.

公开(公告)号：US20170281528A1

公开(公告)日：2017-10-05

申请号：US15625541

申请日：2017-06-16

申请人： Jordan Fabrikant

发明人： Jordan Fabrikant

IPC分类号： A61K8/98 ,  A61L27/38 ,  A61L27/54 ,  B33Y70/00 ,  B29C67/00 ,  B33Y10/00 ,  B33Y80/00 ,  A61Q7/00 ,  C12N5/071

CPC分类号： A61K8/985 ,  A61K35/36 ,  A61L27/3804 ,  A61L27/3813 ,  A61L27/3834 ,  A61L27/3891 ,  A61L27/54 ,  A61Q7/00 ,  B29K2089/00 ,  B29K2995/0056 ,  B33Y70/00 ,  B33Y80/00 ,  C12N5/0062 ,  C12N5/0627 ,  C12N2501/10 ,  C12N2502/09 ,  C12N2506/094

摘要： The present invention recognizes that there exists a long felt need for reliable hair growth methods and compositions that do not suffer from side effects and limitations of current technologies, such as surgery using a subject's own hair and pharmaceutical compositions. A first aspect of the present invention is a method of making at least one three dimensional collection of cells capable of forming a functional hair follicle. A second aspect of the present invention is a product produced by the method of making at least one three dimensional collection of cells capable of forming a functional hair follicle of the present invention. A third aspect of the present invention is a method of making at least one functional hair follicle. A fourth aspect of the present invention is a product produced by the method of making at least one functional hair follicle of the present invention. A fifth aspect of the present invention is a method of hair growth in a subject using at least one three dimensional collection of cells capable of forming a functional hair follicle of the present invention. A sixth aspect of the present invention is a method of hair growth in a subject using at least one functional hair follicle of the present invention.